Circulation Publishes 6-Month Outcomes from First-in-Human VCAS Trial of FieldForceâ„¢ Pulsed Field Ablation System: 82% Freedom from VT/VF Recurrence and 98% Reduction in Burden
- hollywindler
- Oct 10
- 1 min read
CARDIFF-BY-THE-SEA, Calif. and PHILADELPHIA, Oct. 10, 2025 /PRNewswire/ -- Field Medical, Inc. today announced that Circulation has published six-month outcomes from the Ventricular Catheter Ablation Study (VCAS), the first-in-human evaluation of its FieldForceâ„¢ Ablation System for ventricular tachycardia (VT). Results were also presented as a late-breaking trial at the 20th Annual International Symposium on Ventricular Arrhythmias (VT Symposium).
Read the full press release here.